TY - JOUR
T1 - Management of acute graft-versus-host disease in children
AU - Carpenter, Paul A.
AU - MacMillan, Margaret L.
PY - 2010/2
Y1 - 2010/2
N2 - Acute graft-versus-host disease (aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT) in children. Although 30% to 50% of children respond to corticosteroids as initial therapy, the optimal initial or second-line therapies have not yet been determined. Newer approaches with combination therapy, novel agents, monoclonal antibodies, and/or cellular therapies show some promise but require prospective well-designed trials that include children to establish their efficacy. This article reviews the clinical presentation, treatment, and practical management guidelines for children with aGVHD.
AB - Acute graft-versus-host disease (aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT) in children. Although 30% to 50% of children respond to corticosteroids as initial therapy, the optimal initial or second-line therapies have not yet been determined. Newer approaches with combination therapy, novel agents, monoclonal antibodies, and/or cellular therapies show some promise but require prospective well-designed trials that include children to establish their efficacy. This article reviews the clinical presentation, treatment, and practical management guidelines for children with aGVHD.
KW - Acute GVHD
KW - Children
KW - Graft-versus-host disease
KW - Management
UR - http://www.scopus.com/inward/record.url?scp=77951075744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951075744&partnerID=8YFLogxK
U2 - 10.1016/j.pcl.2009.11.007
DO - 10.1016/j.pcl.2009.11.007
M3 - Review article
C2 - 20307721
AN - SCOPUS:77951075744
SN - 0031-3955
VL - 57
SP - 273
EP - 295
JO - Pediatric Clinics of North America
JF - Pediatric Clinics of North America
IS - 1
ER -